SUCLG2 knockdown suppressed NE differentiation in prostate cancer cells and reduced tumor growth in a xenograft model.[3] SUCLA2 deletion induced a significant metabolic shift, including lower mitochondrial respiratory activity.[26] However, it is currently unclear whether there is a functional difference between the two proteins in cancer progression. Here, SUCLA2 is linked to prostate cancer.